A phase I clinical trial currently investigates GPRC5D-directed CAR-T cell therapy (MCARH109) in relapsed/refractory multiple myeloma, including patients who have received prior BCMA-targeted therapies (NCT04555551). Here, GPRC5D is linked to plasma cell myeloma.